Yong Lu

Yong Lu

Auto-generated profile, based on publicly available information

Yong Lu

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2016 in Nature Communications
Verified
Journal Article
Open access
YZYinghua Zhao
Yinghua Zhao
XCXiao Chu
Xiao Chu
JCJintong Chen
Jintong Chen
YWYing Wang
Ying Wang
SGSujun Gao
Sujun Gao
SWSiqing Wang
Siqing Wang
Dectin-1 signalling in dendritic cells (DCs) has an important role in triggering protective antifungal Th17 responses. However, whether dectin-1 directs DCs to prime antitumour Th9 cells remains unclear. Here, we show that DCs activated by dectin-1 agonists potently promote naive CD4+ T cells to differentiate into Th9 cells. Abrogation of dectin-1 in DCs completely abolishes their Th9-polarizing capability in response to dectin-1 agonist curdlan. Notably, dectin-1 stimulation of DCs upregulates TNFSF15 and OX40L, which are essential for dectin-1-activated DC-induced Th9 cell priming. Mechanistically, dectin-1 activates Syk, Raf1 and NF-κB signalling pathways, resulting in increased p50 and RelB nuclear translocation and TNFSF15 and OX40L expression. Furthermore, immunization of tumour-bearing mice with dectin-1-activated DCs induces potent antitumour response that depends on Th9 cells and IL-9 induced by dectin-1-activated DCs in vivo. Our results identify dectin-1-activated DCs as a powerful inducer of Th9 cells and antitumour immunity and may have important clinical implications.

31 May 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
BHBangxing Hong
Bangxing Hong
HLHong Li
Hong Li
YLYong Lu
Yong Lu
MZMingjun Zhang
Mingjun Zhang
YZYuhuan Zheng
Yuhuan Zheng
QYQing Yi
Qing Yi
Interferon (IFN)-γ-mediated immune response plays an important role in tumor immunosurveillance. However, the regulation of IFN-γ-mediated tumorigenesis and immune response remains elusive. USP18, an interferon stimulating response element, regulates IFN-α-mediated signaling in anti-viral immune response, but its role in IFN-γ-mediated tumorigenesis and anti-tumor immune response is unknown. In this study, USP18 in tumorigenesis and anti-tumor immune response was comprehensively appraised in vivo by overexpression or downregulation its expression in murine B16 melanoma tumor model in immunocompetent and immunodeficient mice. Ectopic expression or downregulation of USP18 in B16 melanoma tumor cells inhibited or promoted tumorigenesis, respectively, in immunocompetent mice. USP18 expression in B16 melanoma tumor cells regulated IFN-γ-mediated immunoediting, including upregulating MHC class-I expression, reducing tumor cell-mediated inhibition of T cell proliferation and activation, and suppressing PD-1 expression in CD4+ and CD8+ T cells in tumor-bearing mice. USP18 expression in B16 melanoma tumor cells also enhanced CTL activity during adoptive immunotherapy by prolonging the persistence and enhancing the activity of adoptively transferred CTLs and by reducing CTL exhaustion in the tumor microenvironment. Mechanistic studies demonstrated that USP18 suppressed tumor cell-mediated immune inhibition by activating T cells, inhibiting T-cell exhaustion, and reducing dendritic cell tolerance, thus sensitizing tumor cells to immunosurveillance and immunotherapy. These findings suggest that stimulating USP18 is a feasible approach to induce B16 melanoma specific immune response.

1 September 2016 in International Immunopharmacology
Verified
Journal Article
Closed access
LWLijuan Wang
Lijuan Wang
XHXueyuan Heng
Xueyuan Heng
YLYong Lu
Yong Lu
ZCZhen Cai
Zhen Cai
QYQing Yi
Qing Yi
FCFengyuan Che
Fengyuan Che

29 April 2014 in MOJ Immunology
Verified
Journal Article
Open access
YLYong Lu
Yong Lu